Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure.

Date publication

octobre 2016

Journal

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HABERSETZER François , Dr MINELLO Anne

Tous les auteurs :
Dumortier J, Bailly F, Pageaux GP, Vallet-Pichard A, Radenne S, Habersetzer F, Gagnieu MC, Grangé JD, Minello A, Guillaud O, Kamar N, Alric L, Leroy V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27760839

Résumé

Chronic hepatitis C virus (HCV) infection is the most common chronic liver disease in patients with end-stage renal disease (ESRD). Over the last few years, second-generation direct-acting antivirals have been revolutionary in the treatment of hepatitis C, and sofosbuvir (SOF) is the backbone of most modern treatment strategies. Since SOF is eliminated through the kidney, the aim of this multicentre retrospective study was to assess its antiviral efficacy and safety in HCV-infected patients with severe renal failure [including haemodialysis (HD) patients].

Référence

Nephrol. Dial. Transplant.. 2016 Oct;: